My research sits at the intersection of neurodegenerative disease biology and smart biomaterials. I develop injectable and stimuli-responsive hydrogels and biointerfaces to deliver small molecules and extracellular vesicles/exosomes with spatiotemporal control, aiming to modulate oxidative stress, mitochondrial dysfunction, and innate immune pathways (e.g., NF-κB/NLRP3) implicated in Parkinson’s and Alzheimer’s disease. Mechanistically, my work emphasizes quantitative evaluation of redox balance, mitochondrial integrity, and neuroinflammatory signaling in relevant cellular models to guide biomaterial design and therapeutic optimization. As an ongoing and future direction, I am establishing organ-on-a-chip microphysiological platforms (e.g., brain-on-a-chip) that integrate iPSC-derived neurons, glia, and immune components under controlled tissue mechanics and perfusion, enabling more predictive disease modeling and preclinical screening with standardized functional readouts.
My research sits at the intersection of neurodegenerative disease biology and smart biomaterials. I develop injectable and stimuli-responsive hydrogels and biointerfaces to deliver small molecules and extracellular vesicles/exosomes with spatiotemporal control, aiming to modulate oxidative stress, mitochondrial dysfunction, and innate immune pathways (e.g., NF-κB/NLRP3) implicated in Parkinson’s and Alzheimer’s disease. Mechanistically, my work emphasizes quantitative evaluation of redox balance, mitochondrial integrity, and neuroinflammatory signaling in relevant cellular models to guide biomaterial design and therapeutic optimization. As an ongoing and future direction, I am establishing organ-on-a-chip microphysiological platforms (e.g., brain-on-a-chip) that integrate iPSC-derived neurons, glia, and immune components under controlled tissue mechanics and perfusion, enabling more predictive disease modeling and preclinical screening with standardized functional readouts.